Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

The emergence of degrader-antibody conjugates (DACs) has attracted much attention, with a potential to transform the ...

Genmab A/S (Nasdaq: GMAB) announced today that AbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

Carbogen Amcis has been granted a GMP certificate for its 9,500m² Saint-Beauzire facility, supporting a wide range of ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

With over 15 years of expertise in developing injectable and liquid pharmaceutical forms, CARBOGEN AMCIS’ Saint-Beauzire site provides tailored solutions for pre-clinical and clinical trials and small ...

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

BioAtla (NASDAQ:BCAB – Get Free Report) is anticipated to announce its quarterly earnings results after the market closes on ...

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit ...